Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec;3(12):1505-21.
doi: 10.18632/oncotarget.802.

Advances in targeting signal transduction pathways

James A McCubrey  1 , Linda S Steelman, William H Chappell, Lin Sun, Nicole M Davis, Stephen L Abrams, Richard A Franklin, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto M Martelli, Massimo Libra, Saverio Candido, Giovanni Ligresti, Grazia Malaponte, Maria C Mazzarino, Paolo Fagone, Marco Donia, Ferdinando Nicoletti, Jerry Polesel, Renato Talamini, Jörg Bäsecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Michele, Agostino Tafuri, Joanna Dulińska-Litewka, Piotr Laidler, Antonio B D'Assoro, Lyudmyla Drobot, Drobot Umezawa, Giuseppe Montalto, Melchiorre Cervello, Zoya N Demidenko
Affiliations
Review

Advances in targeting signal transduction pathways

James A McCubrey et al. Oncotarget. 2012 Dec.

Abstract

Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some of the highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies.

PubMed Disclaimer

References

    1. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012;3:954–987. - PMC - PubMed
    1. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Basecke J, Mijatovic S, Maksimovic-Ivanic D, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget. 2012;3:1068–1111. - PMC - PubMed
    1. Leonardi GC, Candido S, Carbone M, Raiti F, Colaianni V, Garozzo S, Cinà D, McCubrey JA, Libra M. BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies. Mol Med Report. 2012;6:687–694. - PubMed
    1. Maira F, Catania A, Candido S, Russo AE, McCubrey JA, Libra M, Malaponte G, Fenga C. Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs. Curr Drug Deliv. 2012;9:17–29. - PubMed
    1. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080–1094. - PubMed

Publication types

Substances